Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Prexasertib mesylate monohydrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prexasertib mesylate monohydrate overview
Prexasertib (LY-2606368 monomesylate monohydrate) is under development for the treatment of pediatric CNS tumors including refractory or recurrent medulloblastoma, metastatic ovarian cancer, endometrial cancer, metastatic and unresectable urothelial carcinoma, peritoneal cancer, fallopian tube cancer, bladder cancer, cervical cancer, squamous cell carcinoma of head and neck cancer and squamous cell cancer of the anus. It was also under development for metastatic colorectal cancer, squamous cell carcinomas including squamous non-small cell lung cancer, epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, extensive stage disease small-cell lung cancer, metastatic castrate-resistant prostate cancer, metastatic triple negative breast cancer, relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome and pediatric CNS tumors including neuroblastoma, childhood rhabdomyosarcoma. The drug candidate is administered intravenously. It is a new chemical entity (NCE) which acts by targeting Chk1 and Chk2 protein kinase.
Acrivon Therapeutics overview
Acrivon Therapeutics (Acrivon) is a biotechnology company that specializing in drug development through early clinical treatment success. Acrivon is headquartered in Watertown, Massachusetts, the US.
For a complete picture of Prexasertib mesylate monohydrate’s drug-specific PTSR and LoA scores, buy the report here.